Gastric Reflux Clinical Trial
— AQUAAOfficial title:
Study Off Efficacy and Rapidity of Action of a Product With Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric Acidity (pH), Symptoms of Gastric Reflux and Hyperacidity
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 30, 2023 |
Est. primary completion date | May 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients of both sexes over 18 years of age - Patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake - Patients not on proton pump blockers or H2-receptor antagonists - Patients able to understand the study implications and who sign the informed consent. Exclusion Criteria: - Pregnant or nursing women - Patients who are currently using or have used other medications or antacid products for the treatment of reflux and hyperacidity symptoms within 7 days prior to enrolment in this study. - Patients treated with antihypertensive drugs, calcium channel blockers or non-steroidal anti-inflammatory drugs (NSAIDs) - Patients with hypercalcaemia, hypertension, renal failure or other conditions in which the use of the components of the investigational product is not recommended. - Patients with serious diseases that, in the physician's opinion, could interfere with the results of the study or prevent their participation in it. |
Country | Name | City | State |
---|---|---|---|
Spain | Oriol Armengol | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Uriach Consumer Healthcare |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intensity of acidity/heartburn | Change in intensity of acidity/heartburn before and after taking the treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) | At the beginning and at the end of treatment, an average of 7±1 days in patients | |
Primary | Time from treatment intake to resolution or maximum decrease in acidity/heartburn | Change in time from treatment intake to resolution or maximum decrease in acidity/heartburn as assessed by the patient using a 3-point Likert scale (<1 minute, 1-5 minutes, >5 minutes) | At the beginning and at the end of treatment, an average of 7±1 days in patients | |
Primary | Time elapsed between product intake and intragastric pH > 4 | Change in minutes of the time elapsed between product intake and intragastric pH > 4 | Baseline visit | |
Primary | Time with intragastric pH > 4 for 20 minutes before and after product intake | Total time in minutes of the time in intragastric pH > 4 for 20 minutes before and after product intake | Baseline visit | |
Secondary | Demographic data | Sex, ethnicity and age data of patients | Baseline visit | |
Secondary | Time of tablet duration in the mouth before complete dissolution | Change in time of tablet duration in the mouth before complete dissolution, assessed using a 4-point Likert scale (< 1 minute, 1-3 minutes, 3-5 min, >5 minutes) | At the beginning and at the end of treatment, an average of 7±1 days in patients | |
Secondary | Number of daytime and nightime episodes of acidity/heartburn | Change in number of daytime and nightime episodes of acidity/heartburn (information recorded in the Patient Diary) | An average of 7±1 days in patients | |
Secondary | Intensity of reflux before and after treatment | Change in intensity of reflux before and after treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) | At the beginning and at the end of treatment, an average of 7±1 days in patients | |
Secondary | Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score | Change in Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score. Between 0 and 8 in symptoms questions the score don't mean GERD, more than 8 mean GERD or severe GERD if in impact questions the score is more than 2. | At the beginning and at the end of treatment, an average of 7±1 days in patients | |
Secondary | Number of Participants With Adverse Events | Number of Participants With Adverse Events as a Measure of Safety and Tolerability | From the beginning to the end of treatment, an average of 7±1 days in patients | |
Secondary | Degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product | Assessment of degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product using 5-point Likert scales (0=very dissatisfied, 1=dissatisfied, 2=indifferent, 3=satisfied, 4=very satisfied). | Through study completion, an average of 6 months | |
Secondary | Mean intragastric pH | Change in mean intragastric pH for 20 minutes before and after product intake | Baseline visit | |
Secondary | Number of episodes of GER (intraoesophageal pH < 4) | Change in the number of episodes of GER (intraoesophageal pH < 4). Evaluation 20 minutes before and after taking the product | Baseline visit | |
Secondary | Time with oesophageal pH < 4 | Change in the time with oesophageal pH < 4. Evaluation 20 minutes before and after taking the product | Baseline visit | |
Secondary | Longest reflux episode (oesophageal pH <4) | Change in the time of longest reflux episode (oesophageal pH <4). Evaluation 20 minutes before and after taking the product | Baseline visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05320796 -
The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass
|
Phase 4 | |
Withdrawn |
NCT05016076 -
Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05500196 -
Impact of Gastric Length of Myotomy During POEM on Gastroesophageal Reflux
|
||
Not yet recruiting |
NCT04105894 -
Gastric Reflux and Sinonasal Symptoms
|